Applied Filters
The fall of COVID-19 and the rise of antimicrobial resistance
With evidence of antimicrobial resistance increasing, can innovation incentives drive pharma to fight back? Donald McNab and Mark Schuster of Marks & Clerk explore.
Will authorised biologics deter biosimilars? Utilising JFTC’s expertise in drug pricing
Should the MHLW and CSIMC consider competition in drug pricing, it would be necessary to formulate systems to utilise the expertise of a competition expert, namely the Japan Fair Trade Commission, says Takanori Abe of Abe & Partners.
SurgiSil: Lip implant case shows looks can be deceiving
A seemingly small decision by the US Court of Appeals for the Federal Circuit could have a big impact on owners of design patents, explains Elizabeth Ferrill of Finnegan.
When alliances fail, is arbitration the answer?
The global pandemic has increased collaboration and a new wave of disputes is likely. Arbitration is well placed to help, argue Kate Davies McGill, Gaela Gehring Flores and Paul Keller of Allen & Overy
UN International Day of Women and Girls in Science: a perspective
Chiara Banas, patent scientist at EIP, queries the gender gap in life sciences, and shares how her own experiences could prefigure change.
Pandemic blues: the global approach to COVID-related IP
While the effort to secure greater vaccine and treatment equality via an IP waiver is admirable, it could stifle innovation and create long-term problems, say Matthew Howell and Lauren Griffin of Alston & Bird.
Amendments to Chinese Patents Law for the Life Sciences
Recent changes to patent law in China sees registration, review and litigation fall in line with established international IP systems, say Venable partners Keith Haddaway and Christopher Loh.
Conference preview: ACI breaks down Section 337 at the 13th Annual Practitioners’ Think Tank
Making sense of the newest Section 337 developments will be a key focus of The American Conference Institute’s 13th Annual Practitioners’ Think Tank on ITC Litigation and Enforcement.
Navigating patent eligibility in digital healthcare
Patent applicants with digital health inventions need to remember that being useful and novel may not be enough, warn Linda Thayer, Aaron Capron and Sneha Nyshadham of Finnegan, Henderson, Farabow, Garrett & Dunner.
The curious case of Wuhan’s Institute of Virology and remdesivir
Changes to China’s patent laws and a filing by a Wuhan lab involving Gilead’s remdesivir have set up an interesting patent race, says Thomas Moga of Dykema.
